Compare Crispr Therapeutics AG (CRSP) vs Fox Corp Class A (FOXA) Price & Performance

CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.

The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.

FOXA trades at $62.70, up 1.0% today, with a bearish technical signal but strong fundamentals including a P/E of 16.55 and net income margin of 9.84%. Recent earnings beats and a consensus analyst price target of $72.00 suggest upside potential, though the pending Roku acquisition faces DOJ scrutiny, adding regulatory risk. Cash flow improved in 2025, but a projected net cash outflow in 2026 warrants monitoring.

The outlook is mixed: solid profitability and analyst support contrast with technical weakness and acquisition uncertainty. Investors may find value if the Roku deal proceeds smoothly, but regulatory delays or integration challenges pose significant downside risks to near-term performance.